HealthCare Global Enterprises (HCG), has acquired an additional 60.9% in Suchirayu Healthcare Solutions Hubli, thereby becoming a majority stake owner from its existing 17.7% to 78.6%.

Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds. HCG has operated and maintained the said entity's hospital since August 2017 and had the right to increase its stake up to 80% in July 2022. HCG also owns and operates a standalone Cancer Centre at Hubli, and the acquisition is expected to create synergetic benefits and market leadership in the geography. HCG and the current group of promoter doctors decided to bring HCG on board to collectively enhance the value moving forward. HCG has a successful track record of integrating acquisitions, and this acquisition will be in line with HCG's strategy going forward.

HCG is one of India's largest oncology-focused private hospital groups, with a significant network of oncology centers located across leading cities and treating thousands of 'new cancer patients every year.

Dr. BS Ajaikumar, Executive Chairman of HCG, said, "HCG continues on its path to optimize capital allocations around cancer care and strengthen its pre-eminent position around the length and breadth of the country. M&A has been a core part of our strategy, and we have demonstrated our capability to integrate acquisitions. Having operated Suchirayu for the past four years with successful patient outcomes and desired financial results, acquiring a majority was a logical step in cementing our presence in the region.’’

Raj Gore, CEO of HCG, added, "India has an acute problem of access to quality healthcare with a correct diagnosis. This is visible in the regional geographies. With its high-end healthcare focus on tier 2 and tier 3 towns, HCG has been at the forefront of penetrating the regional markets. We have transformed Suchirayu into North Karnataka's leading hospital in a short period through our focus on quality patient outcomes. During this time, we have been able to more than double the revenue and enhance EBITDA margins to over 20% from a single-digit margin since we took over the operations.’’